EGFR and non-small cell lung carcinoma: Reports indicate that PARPI (Niraparib) serves not only as a potential radiosensitizer to amplify unrepaired DNA damage but also augments the effect of radiotherapy (RT) with reduced toxicity [53], thereby impeding the growth of EGFR-mutated NSCLC tumors.